{"id":355111,"date":"2026-11-19T14:03:50","date_gmt":"2026-11-19T08:33:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355111"},"modified":"2026-11-19T14:03:50","modified_gmt":"2026-11-19T08:33:50","slug":"albert-david-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/","title":{"rendered":"Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Albert David Stock Snapshot (18 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b9759.90<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9931.85 \/ \u20b9579.90<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b9430 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 15.1 vs 51.5<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9100.83 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b92.88 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Albert David analyst review 2027<\/strong> finds no brokerage coverage as of November 2026. Q2 FY27 sales rose about 15.6% to \u20b9100.83 crore and net profit was \u20b92.88 crore, against a loss of \u20b93.30 crore a year ago. Operating margin improved to 11.6% from 2.9%, though a high tax rate of about 43% held back profit. H1 FY27 profit was about \u20b935 crore, helped by a much stronger June quarter. At \u20b9759.90, the stock trades at about 15 times earnings and close to book value, so the <strong>Albert David share price target 2027<\/strong> question depends on steady margins.<\/p>\n<\/div>\n<p>The <strong>Albert David analyst review 2027<\/strong> covers a Kolkata-based drug maker that is part of the Kothari group and makes medicines including injectables, infusions and other formulations. Readers searching for an <strong>Albert David share price target 2027<\/strong> will not find a named <strong>brokerage<\/strong> figure, so results and valuation guide this review.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/albertdavd\/albert-david-ltd-share-price-today\">Albert David<\/a> closed at \u20b9759.90 on 18 November 2026, about 18% below its 52-week high of \u20b9931.85 and about 31% above its low of \u20b9579.90. This Albert David analyst review 2027 covers the September quarter and the <strong>Albert David stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=albert-david-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_Analysts_Say_in_the_Albert_David_Analyst_Review_2027\" title=\"What Analysts Say in the Albert David Analyst Review 2027\">What Analysts Say in the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Q2_FY27_Results_in_the_Albert_David_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Albert David Analyst Review 2027\">Q2 FY27 Results in the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#How_Albert_David_Makes_Money\" title=\"How Albert David Makes Money\">How Albert David Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Growth_Triggers_in_the_Albert_David_Analyst_Review_2027\" title=\"Growth Triggers in the Albert David Analyst Review 2027\">Growth Triggers in the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Key_Risks_in_the_Albert_David_Analyst_Review_2027\" title=\"Key Risks in the Albert David Analyst Review 2027\">Key Risks in the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Albert_David_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Albert David Analyst Review 2027: Stock at a Glance\">Albert David Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_to_Watch_After_the_Albert_David_Analyst_Review_2027\" title=\"What to Watch After the Albert David Analyst Review 2027\">What to Watch After the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Final_Word_on_the_Albert_David_Analyst_Review_2027\" title=\"Final Word on the Albert David Analyst Review 2027\">Final Word on the Albert David Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_does_the_Albert_David_analyst_review_2027_show\" title=\"What does the Albert David analyst review 2027 show?\">What does the Albert David analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Is_there_an_Albert_David_share_price_target_2027_from_brokerages\" title=\"Is there an Albert David share price target 2027 from brokerages?\">Is there an Albert David share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_does_Albert_David_make\" title=\"What does Albert David make?\">What does Albert David make?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Why_was_Albert_Davids_Q2_profit_low_despite_higher_margins\" title=\"Why was Albert David&#8217;s Q2 profit low despite higher margins?\">Why was Albert David&#8217;s Q2 profit low despite higher margins?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#Is_Albert_David_stock_undervalued_based_on_the_Albert_David_analyst_review_2027\" title=\"Is Albert David stock undervalued based on the Albert David analyst review 2027?\">Is Albert David stock undervalued based on the Albert David analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_risks_does_the_Albert_David_analyst_review_2027_highlight\" title=\"What risks does the Albert David analyst review 2027 highlight?\">What risks does the Albert David analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/albert-david-analyst-review\/#What_should_investors_track_after_the_Albert_David_analyst_review_2027\" title=\"What should investors track after the Albert David analyst review 2027?\">What should investors track after the Albert David analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Albert_David_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No <strong>brokerage<\/strong> covers Albert David, and institutions hold only about 2.2%. With a market value of about \u20b9430 crore, it sits outside most research lists.<\/p>\n<p>The stock trades at about 15 times trailing earnings, far below the industry level of about 51.5, and at about 1.03 times <strong>book value<\/strong> of \u20b9738.86 per share. This Albert David analyst review 2027 explains why the market values it near book despite recent profit growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Albert_David_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sales<\/td>\n<td>\u20b9100.83 crore<\/td>\n<td>\u20b987.24 crore<\/td>\n<td>Up 15.6%<\/td>\n<\/tr>\n<tr>\n<td>Operating profit<\/td>\n<td>About \u20b912 crore<\/td>\n<td>About \u20b92.5 crore<\/td>\n<td>Up sharply<\/td>\n<\/tr>\n<tr>\n<td>Operating margin<\/td>\n<td>11.6%<\/td>\n<td>2.9%<\/td>\n<td>Up 8.7 points<\/td>\n<\/tr>\n<tr>\n<td>Net profit<\/td>\n<td>\u20b92.88 crore<\/td>\n<td>Loss of \u20b93.30 crore<\/td>\n<td>Back to profit<\/td>\n<\/tr>\n<tr>\n<td>EPS<\/td>\n<td>\u20b95.05<\/td>\n<td>Negative<\/td>\n<td>Back to positive<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Sales rose 15.6% and the operating margin jumped to 11.6% from 2.9%. <strong>Net profit<\/strong> turned positive at \u20b92.88 crore, though a tax rate of about 43%, well above the usual level near 20%, reduced the figure.<\/p>\n<p>Sales have now grown year on year for four quarters in a row. For this Albert David analyst review 2027, the margin recovery is the most important change.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Albert_David_Makes_Money\"><\/span><strong>How Albert David Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Albert David makes and sells medicines, mainly in India.<\/p>\n<ul>\n<li><strong>Injectables and infusions:<\/strong> hospital products such as IV fluids and injections.<\/li>\n<li><strong>Formulations:<\/strong> tablets, capsules and other branded medicines.<\/li>\n<li><strong>Hospital supply:<\/strong> sales to hospitals and institutions.<\/li>\n<li><strong>Doctor-led sales:<\/strong> branded medicines promoted to doctors through a field force.<\/li>\n<\/ul>\n<p>Sales were about \u20b9101.34 crore in the June quarter, up about 44%, and \u20b9100.83 crore in September, so H1 FY27 sales reached about \u20b9202 crore against about \u20b9158 crore a year earlier. H1 FY27 profit was about \u20b935 crore against about \u20b94.6 crore. Those numbers anchor this Albert David analyst review 2027.<\/p>\n<p>Most of the half-year profit came from the June quarter, which was much stronger than September. Investors should treat the H1 figure with care, because one quarter carried most of the gain and the September quarter alone earned less than \u20b93 crore.<\/p>\n<p>The December 2025 quarter offers another reference point, with sales of about \u20b989.93 crore, an operating margin of about 12% and profit of \u20b915.30 crore. That suggests margins near 12% are achievable, but quarterly profit can still swing on tax and other items.<\/p>\n<p>The balance sheet is improving. Borrowings fell about 18% to about \u20b934 crore from September 2025, and <strong>debt to equity<\/strong> is low at about 0.08. With little debt, most of any margin gain can flow through to profit.<\/p>\n<p>Return on equity of about 6.8% is the main reason the stock trades close to <strong>book value<\/strong>. If margins stay near 12% for several quarters, returns would rise and the gap to industry valuations could narrow.<\/p>\n<p>Hospital products such as infusions tend to be steady, because hospitals reorder them regularly regardless of the economic cycle. That gives the business a stable base, while margins depend on raw material costs, plant use and how much of the portfolio comes from higher-margin branded products.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Albert_David_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margin recovery:<\/strong> operating margin up to 11.6%.<\/li>\n<li><strong>Sales growth:<\/strong> four straight quarters of year-on-year growth.<\/li>\n<li><strong>Lower debt:<\/strong> borrowings down about 18% to \u20b934 crore.<\/li>\n<li><strong>Tax normalising:<\/strong> a lower tax rate would lift reported profit.<\/li>\n<li><strong>Valuation gap:<\/strong> a <strong>P\/E<\/strong> far below the industry feeds the Albert David share price target 2027 debate.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Albert_David_Analyst_Review_2027\"><\/span><strong>Key Risks in the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Lumpy profits:<\/strong> H1 profit came mostly from one quarter.<\/li>\n<li><strong>High tax:<\/strong> a 43% rate held back Q2 profit.<\/li>\n<li><strong>Low returns:<\/strong> return on equity of about 6.8%.<\/li>\n<li><strong>Price controls:<\/strong> government pricing rules can limit margins on some medicines.<\/li>\n<li><strong>Low liquidity:<\/strong> small institutional holding, a caution in the Albert David analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Albert David With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Albert_David_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Albert David Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (18 Nov 2026 close)<\/td>\n<td>\u20b9759.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9931.85 \/ \u20b9579.90<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b9430 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>15.1<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>51.5<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>1.03<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>6.8%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.08<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b950.35<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 Sales \/ Net Profit<\/td>\n<td>About \u20b9202 crore \/ \u20b935 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 15 is less than a third of the industry level, and price to <strong>book value<\/strong> is about 1.03. In this Albert David analyst review 2027, low returns and uneven profit explain the gap.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>62.24%<\/td>\n<td>62.24%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>0.60%<\/td>\n<td>0.60%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>1.66%<\/td>\n<td>1.64%<\/td>\n<td>Flat<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>35.50%<\/td>\n<td>35.53%<\/td>\n<td>Flat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group holds 62.24%, led by Kothari Investment and Industries at 41.4% and Anand Vardhan Kothari at 9.9%. Stable holdings are a neutral point in the Albert David analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Albert_David_Analyst_Review_2027\"><\/span><strong>What to Watch After the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margins:<\/strong> operating margin holding near 12%.<\/li>\n<li><strong>Tax rate:<\/strong> a return towards normal levels.<\/li>\n<li><strong>Sales growth:<\/strong> a fifth straight quarter of growth.<\/li>\n<li><strong>Debt:<\/strong> further cuts in borrowings.<\/li>\n<li><strong>Coverage:<\/strong> any research note would give an Albert David share price target 2027 reference.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Albert_David_Analyst_Review_2027\"><\/span><strong>Final Word on the Albert David Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Albert David analyst review 2027<\/strong> shows a mid-sized drug maker with rising sales, recovering margins and falling debt, though quarterly profit remains uneven. The stock trades near <strong>book value<\/strong> and well below industry multiples.<\/p>\n<p>The <strong>Albert David stock outlook 2027<\/strong> depends on steady margins and more consistent profit. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Albert_David_analyst_review_2027_show\"><\/span><strong>What does the Albert David analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows a return to profit with better margins. Q2 FY27 sales rose about 15.6% to \u20b9100.83 crore and net profit was \u20b92.88 crore. A year earlier, it posted a loss of \u20b93.30 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Albert_David_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Albert David share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No brokerage covers Albert David as of November 2026. The stock closed at \u20b9759.90 on 18 November 2026. Book value per share is about \u20b9738.86.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Albert_David_make\"><\/span><strong>What does Albert David make?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Albert David makes medicines including injectables, infusions, tablets and other formulations. It is a Kolkata-based Kothari group company. H1 FY27 sales were about \u20b9202 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_was_Albert_Davids_Q2_profit_low_despite_higher_margins\"><\/span><strong>Why was Albert David&#8217;s Q2 profit low despite higher margins?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The tax rate was about 43%, well above the usual level near 20%. Operating margin still rose to 11.6% from 2.9%. Net profit was \u20b92.88 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Albert_David_stock_undervalued_based_on_the_Albert_David_analyst_review_2027\"><\/span><strong>Is Albert David stock undervalued based on the Albert David analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The P\/E of about 15 is far below the industry P\/E of about 51.5. Price to book is about 1.03. Low return on equity and uneven profits explain the gap.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Albert_David_analyst_review_2027_highlight\"><\/span><strong>What risks does the Albert David analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are lumpy profits, a high tax rate and low returns. Most H1 FY27 profit came from the June quarter. Government price rules can also limit margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Albert_David_analyst_review_2027\"><\/span><strong>What should investors track after the Albert David analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether operating margin holds near 12% and the tax rate normalises. Watch for a fifth straight quarter of sales growth. Further debt reduction also matters.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Albert David analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows a return to profit with better margins. Q2 FY27 sales rose about 15.6% to \u20b9100.83 crore and net profit was \u20b92.88 crore. A year earlier, it posted a loss of \u20b93.30 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Albert David share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No brokerage covers Albert David as of November 2026. The stock closed at \u20b9759.90 on 18 November 2026. Book value per share is about \u20b9738.86.\"}},{\"@type\":\"Question\",\"name\":\"What does Albert David make?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Albert David makes medicines including injectables, infusions, tablets and other formulations. It is a Kolkata-based Kothari group company. H1 FY27 sales were about \u20b9202 crore.\"}},{\"@type\":\"Question\",\"name\":\"Why was Albert David's Q2 profit low despite higher margins?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The tax rate was about 43%, well above the usual level near 20%. Operating margin still rose to 11.6% from 2.9%. Net profit was \u20b92.88 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Albert David stock undervalued based on the Albert David analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of about 15 is far below the industry P\/E of about 51.5. Price to book is about 1.03. Low return on equity and uneven profits explain the gap.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Albert David analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are lumpy profits, a high tax rate and low returns. Most H1 FY27 profit came from the June quarter. Government price rules can also limit margins.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Albert David analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether operating margin holds near 12% and the tax rate normalises. Watch for a fifth straight quarter of sales growth. Further debt reduction also matters.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Albert David grew Q2 FY27 sales 16% to \u20b9100.83 crore and returned to a \u20b92.88 crore profit after a loss a year ago, as operating margin rose to 11.6%. The Kolkata drug maker trades near book value. With no brokerage coverage, we review results, the business and risks.<\/p>\n","protected":false},"author":34,"featured_media":355110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,26211,4341,6686],"class_list":["post-355111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-albert-david","tag-analyst-review","tag-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355110"],"rank_math_title":["Albert David Share Price Target 2027: Stock Review"],"rank_math_description":["Albert David analyst review 2027: Q2 FY27 sales up 16% to \u20b9100.83 crore, profit \u20b92.88 crore after a loss, margin up to 11.6%, debt falling, valuation and risks."],"rank_math_focus_keyword":["Albert David analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/albert-david-analyst-review-2027-sales-up-16-and-margins-recover-profit-back-in.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355111"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355111\/revisions"}],"predecessor-version":[{"id":355112,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355111\/revisions\/355112"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355110"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}